[go: up one dir, main page]

SG10201912974VA - Viral conjunctivitis treatment using ranpirnase and/or amphinase - Google Patents

Viral conjunctivitis treatment using ranpirnase and/or amphinase

Info

Publication number
SG10201912974VA
SG10201912974VA SG10201912974VA SG10201912974VA SG10201912974VA SG 10201912974V A SG10201912974V A SG 10201912974VA SG 10201912974V A SG10201912974V A SG 10201912974VA SG 10201912974V A SG10201912974V A SG 10201912974VA SG 10201912974V A SG10201912974V A SG 10201912974VA
Authority
SG
Singapore
Prior art keywords
amphinase
ranpirnase
viral conjunctivitis
conjunctivitis treatment
treatment
Prior art date
Application number
SG10201912974VA
Inventor
Brian Strem
Original Assignee
Okogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Okogen Inc filed Critical Okogen Inc
Publication of SG10201912974VA publication Critical patent/SG10201912974VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/27Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/27Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27005Pancreatic ribonuclease (3.1.27.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
SG10201912974VA 2015-09-25 2016-09-26 Viral conjunctivitis treatment using ranpirnase and/or amphinase SG10201912974VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562233267P 2015-09-25 2015-09-25

Publications (1)

Publication Number Publication Date
SG10201912974VA true SG10201912974VA (en) 2020-03-30

Family

ID=58387443

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201912974VA SG10201912974VA (en) 2015-09-25 2016-09-26 Viral conjunctivitis treatment using ranpirnase and/or amphinase

Country Status (12)

Country Link
US (3) US9682130B2 (en)
EP (1) EP3353304B1 (en)
JP (1) JP6794454B2 (en)
KR (1) KR102789464B1 (en)
CN (1) CN108350458B (en)
AU (1) AU2016326750B2 (en)
CA (1) CA2999514A1 (en)
IL (1) IL258237B (en)
MX (1) MX2018003528A (en)
RU (1) RU2733432C1 (en)
SG (1) SG10201912974VA (en)
WO (1) WO2017053923A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019222533A1 (en) * 2018-05-18 2019-11-21 Okogen, Inc. Methods of treating ocular melanoma
CN110038120B (en) * 2019-04-02 2022-12-23 河南师范大学 Application of Leopard Frog Antitumor Enzyme Fusion Protein as a Drug for Treating Tumors
CN110964798B (en) * 2020-03-05 2023-07-07 东北农业大学 A Method for Identifying the Genetic Sex of Northeast Rana Rana Using TRAP Molecular Marker Technology
EP4138882A4 (en) * 2020-04-23 2024-04-10 Okogen, Inc. TREATMENT OF VIRAL CONJUNCTIVITIS
CN116334038B (en) * 2023-04-07 2025-11-11 成都诺恩生物科技有限公司 DNA expression enhancement factor and application thereof
WO2024207543A1 (en) * 2023-04-07 2024-10-10 成都诺恩基因科技有限公司 Recombinant gene for increasing protein expression level and expression duration of co-transfected mrna, and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728805A (en) 1988-04-06 1998-03-17 Alfacell Corp. Pharmaceuticals and method for making them
US5559212A (en) * 1988-04-06 1996-09-24 Alfacell Corporation Frog embryo and egg-derived tumor cell anti-proliferation protein
US5326347A (en) * 1991-08-12 1994-07-05 Cumming J Stuart Intraocular implants
RU2093165C1 (en) * 1993-07-06 1997-10-20 Линд Роберт Мейнгардтович Agent for conjunctivitis treatment
US6271224B1 (en) * 1995-12-21 2001-08-07 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
US6239257B1 (en) 1998-12-30 2001-05-29 Alfacell Corporation Family of proteins belonging to the pancreatic ribonuclease a superfamily
GB9920674D0 (en) * 1999-09-01 1999-11-03 Evolutec Limited Treatment of conjunctivitis
US6175003B1 (en) 1999-09-10 2001-01-16 Alfacell Corporation Nucleic acids encoding ribonucleases and methods of making them
US7229824B2 (en) 2003-07-17 2007-06-12 Alfacell Corporation Ribonucleases and methods of making them recombinantly
EP1891244B1 (en) * 2005-04-13 2010-10-06 Ibis Biosciences, Inc. Compositions for use in identification of adenoviruses
US8518399B2 (en) * 2010-11-17 2013-08-27 Tamir Biotechnology, Inc. Methods of treating infections originating from viruses in the herpesviridae family
US8663964B2 (en) 2011-07-20 2014-03-04 Tamir Biotechnology, Inc. Methods of treating human papillomavirus
DK2898888T3 (en) * 2014-01-22 2019-06-03 Visufarma B V Composition comprising iota-carrageenan against viral conjunctivitis
US9919034B2 (en) * 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
CA2942706C (en) * 2014-03-28 2020-01-14 Tamir Biotechnology, Inc. Rnase for use in treating or preventing viral infections
RU2739392C2 (en) * 2015-06-15 2020-12-23 Ордженезис Инк. Pharmaceutical preparations for treating viral infections of eye

Also Published As

Publication number Publication date
EP3353304B1 (en) 2022-10-19
US20170258876A1 (en) 2017-09-14
CA2999514A1 (en) 2017-03-30
MX2018003528A (en) 2018-11-09
US20220265783A1 (en) 2022-08-25
IL258237A (en) 2018-05-31
CN108350458A (en) 2018-07-31
AU2016326750A1 (en) 2018-04-19
AU2016326750B2 (en) 2022-09-15
US9682130B2 (en) 2017-06-20
JP2018535249A (en) 2018-11-29
WO2017053923A1 (en) 2017-03-30
CN108350458B (en) 2022-06-07
JP6794454B2 (en) 2020-12-02
KR102789464B1 (en) 2025-04-03
IL258237B (en) 2021-06-30
KR20180058791A (en) 2018-06-01
RU2733432C1 (en) 2020-10-01
EP3353304A1 (en) 2018-08-01
EP3353304A4 (en) 2019-05-22
US20170087223A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
IL276679B (en) Viral resistant cells and uses thereof
IL260525B (en) Means and methods for treating hbv
IL273932A (en) Viral treatment and prophylaxis methods
ZA201802854B (en) Authentication methods and sysyems
GB201502137D0 (en) Treatment
GB201608885D0 (en) Treatment
IL258237B (en) Viral conjunctivitis treatment using ranpirnase and/or amphinase
IL249660B (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
GB201522243D0 (en) Treatment
IL247938A0 (en) Onconase for use in treating or preventing viral infections
IL258682B (en) Viral neoepitopes and uses thereof
IL272779A (en) Methods of inactivating viral contaminants
IL266098A (en) Soil treatment
IL258137B1 (en) Means for the treatment of hiv
GB201519450D0 (en) Novel treatment
GB201404372D0 (en) Assay and treatment
GB201803197D0 (en) Viral treatment
GB201508841D0 (en) Treatment
ZA201608406B (en) Enzyme treatment composition
GB201503008D0 (en) Treatment
GB201400311D0 (en) Treating Susceptibility
GB201605354D0 (en) Modified enzyme
IL272420A (en) Methods for treating hcv
GB201520019D0 (en) The genome and self-evolution of AI
GB201617107D0 (en) Treatment